Home › Research › Down syndrome and Alzheimer's
Regional Brain Metabolism across the Alzheimer's Disease Continuum in Down Syndrome
Arriola-Infante JE, Morcillo-Nieto AO, Zsadanyi SE, Franquesa-Mullerat M, Vaqué-Alcázar L, Rozalem-Aranha M, Arranz J, Rodríguez-Baz Í et al.. Annals of neurology, 2025-03-14
Topic: Brain proteins, microglia and lab models
Plain-language summary
Objective The goal was to examine the effect of sociodemographic variables, Alzheimer's disease (AD) clinical stages and pathology on brain metabolism in Down syndrome (DS). Methods We included 71 euploid healthy controls (HC) and 105 adults with DS (67 asymptomatic, 12 prodromal, and 26 with dementia) from the Down-Alzheimer Barcelona Neuroimaging Initiative. Participants underwent [18F]fluorodeoxyglucose positron emission tomography, 3 Tmagnetic resonance imaging, and lumbar puncture to measure cerebrospinal fluid (CSF) biomarkers (ratio beween amyloid β peptide 42 and 40, phosphorylated tau 181, and neurofilament light chain [NfL]). Voxel-wise analyses in SPM12 examined the effects of age, sex, intellectual disability, Alzheimer's clinical stage, and CSF biomarkers on brain metabolism. Results In HC, brain metabolism decreased with age primarily in the frontal lobe. By contrast, a more distributed pattern of metabolic loss was observed in DS with age, predominating in temporoparietal regions. Compared to asymptomatic DS participants, those at the prodromal stage exhibited medial parietal hypometabolism, which later extended to other temporoparietal and frontal regions at the dementia stage. In asymptomatic individuals, we observed a widespread hypometabolism compared to HC, mainly in medial frontal and parietal regions. All CSF biomarkers were closely associated with hypometabolism in regions affected by the disease, with the strongest association observed for NfL in medial parietal structures. Interpretation The brain metabolic decline in DS with age reflects Alzheimer's pathological processes and involves temporoparietal regions in a similar pattern to that found in other forms of AD. Hypometabolism is more tightly related to CSF NfL levels than to core AD biomarkers. ANN NEUROL 2025;98:163-173.
What this study adds
Evidence grade: Low
The record lists 71 participants. In 105 adults with Down syndrome, brain metabolism declined with age in a more distributed pattern than in healthy controls, and those at the prodromal stage showed medial parietal hypometabolism that later extended to other regions at the dementia stage. All measured CSF biomarkers were closely associated with hypometabolism in affected regions, suggesting these imaging and biomarker changes track the progression of Alzheimer's disease in Down syndrome.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Arriola-Infante, J. E., Morcillo-Nieto, A. O., Zsadanyi, S. E., Franquesa-Mullerat, M., Vaqué-Alcázar, L., Rozalem-Aranha, M., et al. (2025). Regional Brain Metabolism across the Alzheimer's Disease Continuum in Down Syndrome. Annals of neurology. https://doi.org/10.1002/ana.27226
Vancouver
Arriola-Infante JE, Morcillo-Nieto AO, Zsadanyi SE, Franquesa-Mullerat M, Vaqué-Alcázar L, Rozalem-Aranha M, et al. Regional Brain Metabolism across the Alzheimer's Disease Continuum in Down Syndrome. Annals of neurology. 2025. doi:10.1002/ana.27226. PMID: 40084922.
BibTeX
@article{arriolainfante2025-40084922,
author = {Arriola-Infante, J. E. and Morcillo-Nieto, A. O. and Zsadanyi, S. E. and Franquesa-Mullerat, M. and Vaqué-Alcázar, L. and Rozalem-Aranha, M. and Arranz, J. and Í, Rodríguez-Baz and others},
title = {{Regional Brain Metabolism across the Alzheimer's Disease Continuum in Down Syndrome}},
journal = {Annals of neurology},
year = {2025},
doi = {10.1002/ana.27226},
pmid = {40084922},
url = {https://doi.org/10.1002/ana.27226}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results In HC, brain metabolism decreased with age primarily in the frontal lobe.
- Compared to asymptomatic DS participants, those at the prodromal stage exhibited medial parietal hypometabolism, which later extended to other temporoparietal and frontal regions at the dementia stage.
- In asymptomatic individuals, we observed a widespread hypometabolism compared to HC, mainly in medial frontal and parietal regions.
- All CSF biomarkers were closely associated with hypometabolism in regions affected by the disease, with the strongest association observed for NfL in medial parietal structures.
Why it matters
In 105 adults with Down syndrome, brain metabolism declined with age in a more distributed pattern than in healthy controls, and those at the prodromal stage showed medial parietal hypometabolism that later extended to other regions at the dementia stage. All measured CSF biomarkers were closely associated with hypometabolism in affected regions, suggesting these imaging and biomarker changes track the progression of Alzheimer's disease in Down syndrome.
Study details
- Participants71
- Evidence strengthLow
How this study scored 45/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Annals of neurology) |
| Journal's citation record | 3 / 4 | Annals of Neurology: journal h-index 437 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 71 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 4 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Alexandre Bejanin: h-index 36 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Universitat de Barcelona: institution h-index 1,049 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40084922) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 17.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Down syndrome and Alzheimer's from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.